Free Trial
CVE:PTF

Pender Growth Fund (PTF) Stock Price, News & Analysis

Pender Growth Fund logo
C$14.00 +0.44 (+3.24%)
As of 07/7/2025

About Pender Growth Fund Stock (CVE:PTF)

Key Stats

Today's Range
C$13.58
C$14.01
50-Day Range
C$9.91
C$14.59
52-Week Range
C$9.29
C$14.99
Volume
1,325 shs
Average Volume
2,942 shs
Market Capitalization
C$101.51 million
P/E Ratio
2.26
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pender Growth Fund and its competitors with MarketBeat's FREE daily newsletter.

PTF Stock News Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
See More Headlines

PTF Stock Analysis - Frequently Asked Questions

Pender Growth Fund's stock was trading at C$11.19 at the start of the year. Since then, PTF stock has increased by 25.1% and is now trading at C$14.00.

Shares of PTF stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pender Growth Fund investors own include Armata Pharmaceuticals (ARMP), BioCardia (BCDA), Bristol Myers Squibb (BMY), Range Cancer Therapeutics ETF (CNCR), Inovio Pharmaceuticals (INO), Insight Select Income Fund (INSI) and Protalix BioTherapeutics (PLX).

Industry, Sector and Symbol

Stock Exchange
CVE
Industry
Asset Management
Sub-Industry
N/A
Current Symbol
CVE:PTF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
C$6.20
Trailing P/E Ratio
2.26
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$44.92 million
Net Margins
90.98%
Pretax Margin
N/A
Return on Equity
49.26%
Return on Assets
25.87%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
51.12

Sales & Book Value

Annual Sales
C$49.38 million
Price / Sales
2.06
Cash Flow
C$1.68 per share
Price / Cash Flow
8.35
Book Value
C$15.08 per share
Price / Book
0.93

Miscellaneous

Outstanding Shares
7,250,430
Free Float
N/A
Market Cap
C$101.51 million
Optionable
Not Optionable
Beta
0.56
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (CVE:PTF) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners